#United States #Biopharmaceutical #Germantown #Precigen #H.C. Wainwright

Precigen's Upcoming Fireside Chat with H.C. Wainwright

On March 31, 2026, Precigen, Inc. (Nasdaq: PGEN), a leader in the biopharmaceutical industry, will be featuring its top executives in a virtual fireside chat hosted by H.C. Wainwright. This event which will take place from 11:00 AM to 12:00 PM ET aims to provide insights into the latest advancements in precision medicine, a field that seeks to transform the treatment of patients with difficult-to-manage diseases.

About Precigen, Inc.

Precigen is at the forefront of biopharmaceutical innovation, dedicated to developing precision medicines that cater to patients with high unmet medical needs. Understanding the intricacies involved in treating such complex diseases, the company aims to turn scientific breakthroughs into commercial realities. With a comprehensive pipeline focusing on therapeutic areas such as immuno-oncology, autoimmune disorders, and infectious diseases, Precigen is committed to changing the landscape of treatment options available to patients.

Dr. Helen Sabzevari, President and CEO, and Phil Tennant, Chief Commercial Officer, will represent Precigen during the chat. Their deep expertise, coupled with their commitment to advancing healthcare, positions them ideally to discuss the company’s strategies and pending developments. They plan to elaborate on their mission of ‘Advancing Medicine with Precision®’, which aligns with the company's goal to meet the needs of patients who require innovative treatments.

Accessing the Event

For those interested in attending the chat, detailed access information is available on Precigen's investor relations website under the Events & Presentations section at investors.precigen.com. This is an excellent opportunity for investors, journalists, and healthcare professionals to gauge the future direction of the company and understand how their innovative approaches are shaping the future of biomedicine.

The Future of Precision Medicine

As the healthcare landscape evolves, the importance of precision medicine becomes increasingly clear. By aiming to personalize treatment for patients, companies like Precigen help tailor medical care to individual characteristics, potentially leading to higher success rates in treatment. During the fireside chat, expect discussions around ongoing projects, such as the anticipated commercialization of PAPZIMEOS™—a therapy designed for recurrent respiratory papillomatosis, which illustrates the potential impact that tailored medicines can have on patient care.

Feedback from previous gatherings indicates a growing interest in how companies are preparing to navigate regulatory landscapes and accelerate drug development processes. As such, the chat presents a stage for asking pertinent questions about financials, projections, and upcoming trials that can change the course of patient treatment.

Conclusion

The upcoming fireside chat on March 31 hosted by H.C. Wainwright promises to offer valuable insights into Precigen’s strategic vision and ongoing commitment to revolutionizing patient care through precision medicine. As we await this discussion, stakeholders are encouraged to engage with the material and consider the implications of innovations being undertaken by companies like Precigen in shaping the future of healthcare.